In OCC 2026 Quest for Truth roundtable, leading experts from China and the United States gather to discuss “Cardiomyopathy: From Misdiagnosis to Precision Medicine”. The session is hosted by Prof. Gang Wu, MD, PhD, Department of Cardiology, Shanghai General Hospital, and co-hosted by Prof. Zeping Qiu, MD, PhD, Department of Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine. Quest for Truth is honored to welcome two distinguished guest speakers: Prof. Martin Maron, MD, PhD, Hypertrophic Cardiomyopathy Center and Research Institute, Tufts Medical Center; and Prof. Wei Jin, MD, PhD, Department of Cardiology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine.
The roundtable focuses on “Cardiomyopathy: From Misdiagnosis to Precision Medicine”, with in-depth discussions on hypertrophic cardiomyopathy (HCM) diagnosis and management, genetic testing, cardiac myosin inhibitors, real-world clinical experience, patient-centered treatment decisions, HCM Centers of Excellence, specialist training, and future directions in precision cardiovascular care.
Prof. Martin Maron’s key message in this segment is that, in the era of cardiac myosin inhibitor (CMI) therapy, treatment goals for hypertrophic cardiomyopathy (HCM) should not be guided by LVOT gradient alone. Instead, the primary focus should be on the patient’s symptoms, daily quality of life, and overall clinical benefit.
He emphasizes that if a patient feels well after starting CMI therapy, even with a small residual LVOT gradient, further dose escalation may not be necessary. Treatment can always be adjusted later if symptoms return.
Experts also discuss aficamten as a next-generation CMI, highlighting its short half-life, wide therapeutic window, favorable safety profile, and flexible dose titration. Based on early clinical experience, aficamten may allow many patients to achieve rapid symptom improvement and meaningful gradient reduction, while supporting a more patient-friendly monitoring approach.